WO2007084435A3 - Methods for treating hepatitis c - Google Patents

Methods for treating hepatitis c Download PDF

Info

Publication number
WO2007084435A3
WO2007084435A3 PCT/US2007/000996 US2007000996W WO2007084435A3 WO 2007084435 A3 WO2007084435 A3 WO 2007084435A3 US 2007000996 W US2007000996 W US 2007000996W WO 2007084435 A3 WO2007084435 A3 WO 2007084435A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
treating hepatitis
compounds
compositions
virus
Prior art date
Application number
PCT/US2007/000996
Other languages
French (fr)
Other versions
WO2007084435A8 (en
WO2007084435A2 (en
Inventor
Gary Mitchell Karp
Peter Seongwoo Hwang
James Jan Takasugi
Hongyu Ren
Richard Gerald Wilde
Anthony Allan Turpoff
Alexander Arefolov
Guangming Chen
Jeffrey Allen Campbell
Original Assignee
Ptc Therapeutics Inc
Gary Mitchell Karp
Peter Seongwoo Hwang
James Jan Takasugi
Hongyu Ren
Richard Gerald Wilde
Anthony Allan Turpoff
Alexander Arefolov
Guangming Chen
Jeffrey Allen Campbell
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US11/331,180 external-priority patent/US7868037B2/en
Application filed by Ptc Therapeutics Inc, Gary Mitchell Karp, Peter Seongwoo Hwang, James Jan Takasugi, Hongyu Ren, Richard Gerald Wilde, Anthony Allan Turpoff, Alexander Arefolov, Guangming Chen, Jeffrey Allen Campbell filed Critical Ptc Therapeutics Inc
Priority to CA002636916A priority Critical patent/CA2636916A1/en
Priority to JP2008550455A priority patent/JP2009523732A/en
Priority to EP07716610A priority patent/EP1979315A2/en
Publication of WO2007084435A2 publication Critical patent/WO2007084435A2/en
Publication of WO2007084435A3 publication Critical patent/WO2007084435A3/en
Publication of WO2007084435A8 publication Critical patent/WO2007084435A8/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Abstract

The present invention provides compounds, pharmaceutical compositions, and methods of using such compounds or compositions for treating infection by a virus, or for affecting viral IRES activity.
PCT/US2007/000996 2006-01-13 2007-01-16 Methods for treating hepatitis c WO2007084435A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CA002636916A CA2636916A1 (en) 2006-01-13 2007-01-16 Methods for treating hepatitis c
JP2008550455A JP2009523732A (en) 2006-01-13 2007-01-16 Treatment method for hepatitis C
EP07716610A EP1979315A2 (en) 2006-01-13 2007-01-16 Methods for treating hepatitis c

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US75852706P 2006-01-13 2006-01-13
US11/331,180 US7868037B2 (en) 2004-07-14 2006-01-13 Methods for treating hepatitis C
US60/758,527 2006-01-13
US11/331,180 2006-01-13
US50/758,527 2006-01-13
US92148307P 2007-01-13 2007-01-13
US60/921,483 2007-01-13
US11/653,435 2007-01-13

Publications (3)

Publication Number Publication Date
WO2007084435A2 WO2007084435A2 (en) 2007-07-26
WO2007084435A3 true WO2007084435A3 (en) 2007-11-08
WO2007084435A8 WO2007084435A8 (en) 2009-11-12

Family

ID=38283923

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/000996 WO2007084435A2 (en) 2006-01-13 2007-01-16 Methods for treating hepatitis c

Country Status (2)

Country Link
JP (1) JP2009523732A (en)
WO (1) WO2007084435A2 (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE543808T1 (en) 2006-12-22 2012-02-15 Schering Corp 5,6-RING-ANNELATED INDOLE DERIVATIVES AND USE THEREOF
US8557848B2 (en) 2006-12-22 2013-10-15 Merck Sharp & Dohme Corp. 4,5-ring annulated indole derivatives for treating or preventing of HCV and related viral infections
KR20090106539A (en) 2006-12-22 2009-10-09 쉐링 코포레이션 4,5-Ring annulated indole derivatives for treating or preventing of HCV and related viral infections
WO2009032125A1 (en) 2007-08-29 2009-03-12 Schering Corporation 2,3-substituted azaindole derivatives for treating viral infections
BRPI0815811A2 (en) 2007-08-29 2015-02-18 Schering Corp SUBSTITUTED INDOL DERIVATIVES AND METHODS OF USE THEREOF
KR20100049667A (en) * 2007-08-29 2010-05-12 쉐링 코포레이션 2,3-substituted indole derivatives for treating viral infections
CN102317285A (en) 2007-11-16 2012-01-11 先灵公司 Substituted indole derivatives of 3-amino-sulfonyl and method of use thereof
CA2705586A1 (en) 2007-11-16 2009-05-22 Schering Corporation 3-heterocyclic substituted indole derivatives and methods of use thereof
US8901139B2 (en) 2008-06-13 2014-12-02 Merck Sharp & Dohme Corp. Tricyclic indole derivatives and methods of use thereof
TWI438200B (en) * 2009-02-17 2014-05-21 必治妥美雅史谷比公司 Hepatitis c virus inhibitors
JP5572725B2 (en) * 2010-03-10 2014-08-13 ブリストル−マイヤーズ スクイブ カンパニー Compounds for the treatment of hepatitis C
WO2016036633A1 (en) 2014-09-05 2016-03-10 Merck Sharp & Dohme Corp. Tetrahydroisoquinoline derivatives useful as inhibitors of diacylglyceride o-acyltransferase 2
EP3188730B1 (en) 2014-09-05 2019-05-01 Merck Sharp & Dohme Corp. Tetrahydroisoquinoline derivatives useful as inhibitors of diacylglyceride o-acyltransferase 2
WO2016036638A1 (en) 2014-09-05 2016-03-10 Merck Sharp & Dohme Corp. Isoquinoline derivatives useful as inhibitors of diacylglyceride o-acyltransferase 2
MX2019005786A (en) 2016-11-18 2019-08-26 Merck Sharp & Dohme Indazole derivatives useful as inhibitors of diacylglyceride o-acyltransferase 2.
WO2018093698A1 (en) 2016-11-18 2018-05-24 Merck Sharp & Dohme Corp. Indole derivatives useful as inhibitors of diacylglyceride o-acyltransferase 2
DK3860998T3 (en) 2018-10-05 2024-03-25 Annapurna Bio Inc Compounds and compositions for treating conditions associated with APJ receptor activity

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003010140A2 (en) * 2001-07-25 2003-02-06 Boehringer Ingelheim (Canada) Ltd. Hepatitis c virus polymerase inhibitors with heterobicyclic structure
WO2004035571A1 (en) * 2002-10-15 2004-04-29 Rigel Pharmaceuticals, Inc. Substituted indoles and their use as hcv inhibitors
WO2004065367A1 (en) * 2003-01-22 2004-08-05 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
US20040186125A1 (en) * 2003-01-22 2004-09-23 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
WO2005034941A1 (en) * 2003-10-10 2005-04-21 Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa Indoles and azaindoles as antiviral agents
WO2006019831A1 (en) * 2004-07-14 2006-02-23 Ptc Therapeutics, Inc. Methods for treating hepatitis c

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003010140A2 (en) * 2001-07-25 2003-02-06 Boehringer Ingelheim (Canada) Ltd. Hepatitis c virus polymerase inhibitors with heterobicyclic structure
WO2004035571A1 (en) * 2002-10-15 2004-04-29 Rigel Pharmaceuticals, Inc. Substituted indoles and their use as hcv inhibitors
WO2004065367A1 (en) * 2003-01-22 2004-08-05 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
US20040186125A1 (en) * 2003-01-22 2004-09-23 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
WO2005034941A1 (en) * 2003-10-10 2005-04-21 Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa Indoles and azaindoles as antiviral agents
WO2006019831A1 (en) * 2004-07-14 2006-02-23 Ptc Therapeutics, Inc. Methods for treating hepatitis c

Also Published As

Publication number Publication date
WO2007084435A8 (en) 2009-11-12
JP2009523732A (en) 2009-06-25
WO2007084435A2 (en) 2007-07-26

Similar Documents

Publication Publication Date Title
WO2007084435A3 (en) Methods for treating hepatitis c
WO2007084413A3 (en) Methods for treating hepatitis c
WO2008127364A3 (en) Antiviral compounds and use thereof
WO2007041632A3 (en) Methods and pharmaceutical compositions for the treatment and prevention of hepatitis c infection
WO2008115281A3 (en) Compounds for treating viral infections
WO2009023179A3 (en) Nitrogen containing bicyclic chemical entities for treating viral infections
TW200602064A (en) Nucleoside derivatives for treating hepatitis C virus infection
WO2008021936A3 (en) Hepatitis c virus inhibitors
WO2007140254A3 (en) Cyclopropyl fused indolobenzazepine hcv ns5b inhibitors
WO2008021927A3 (en) Hepatitis c virus inhibitors
WO2008060927A3 (en) Hepatitis c virus inhibitors
TW200720285A (en) Nucleoside compounds for treating viral infections
WO2007044565A3 (en) Composition and synthesis of new reagents for inhibition of hiv replication
WO2006039668A3 (en) 3-ether and 3-thioether substituted cyclosporin derivatives for the treatment and prevention of hepatitis c infection
AP2406A (en) Macrocydic inhibitors of hepatitis C virus.
WO2007092888A3 (en) Hcv ns5b inhibitors
WO2007120595A3 (en) Amines for the treatment of hcv
MX2009009473A (en) Compounds for the treatment of hepatitis c.
WO2009043354A3 (en) Combination treatment for the treatment of hepatitis c virus infection
TW200745035A (en) Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
WO2006138744A3 (en) Heteroaryl derivatives for treating viruses
WO2009029384A3 (en) Compounds for the treatment of hepatitis c
WO2005115398A3 (en) Hiv integrase inhibitors
WO2011106992A8 (en) Inhibitors of hepatitis c virus ns5b polymerase
WO2007008657A3 (en) Hepatitis c virus inhibitors

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200780008916.X

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2636916

Country of ref document: CA

Ref document number: MX/a/2008/009059

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2008550455

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2007716610

Country of ref document: EP